FORM 3


   UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF
BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or
Section 30(h) of the Investment Company Act of 1940		   OMB APPROVAL
OMB Number:        3235-0104
Expires: January 31, 2005
Estimated average burden hours per response .... 0.5
(Print or Type Responses)
1.   Name and Address of Reporting Person*   2.   Date of Event Requiring Statement
(Month/Day/Year)		   4.   Issuer Name and Ticker or Trading Symbol

 
 
BVF Partners L.P.
 
 
 
 
 
April 14, 2003
 
 
 
Array BioPharma, Inc. ("ARRY")
 
 
 
 
 
 
    (Last)   (First)   (Middle)   3.   I.R.S. Identification Number of Reporting Person, if an entity (voluntary)   5.   Relationship of Reporting Person(s) to Issuer (Check all applicable)   6.   If Amendment, Date of Original
(Month/Day/Year)
227 West Monroe Street, Suite 4800                        Director     X   10% Owner        
(Street)		  
           Officer
              (give title
              below)		            Other
              (specify
              below)		  
                                    7.   Individual or Joint/Group Filing
Chicago, Illinois 60606
          
      (Check Applicable Line)
    (City)   (State)   (Zip)                                        Form filed by One Reporting Person
    X     Form filed by More than One Reporting Person

Table I — Non-Derivative Securities Beneficially Owned

1.   Title of Security
(Instr. 4)		   2.   Amount of Securities
Beneficially Owned
(Instr. 4)		   3.   Ownership Form:
Direct (D) or Indirect (I)
(Instr. 5)		   4.   Nature of Indirect
Beneficial Ownership
(Instr. 5)
    Common Stock       2,939,735   (I)   (1)
                             
                             
                             
                             
                             
                             
                             
                             
                             
                             
                             

*If the form is filed by more than one reporting person, see Instruction 5(b)(v).

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473
(03-99)

Persons who respond to the collection of information contained in this form are not required
to respond unless the form displays a currently valid OMB control number.

Page 1 of 3

FORM 3 (Continued)   Table II — Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
    
1.   Title of Derivative Security
(Instr. 4)		   2.   Date Exercisable and Expiration Date
(Month/Day/Year)		   3.   Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		   4.   Conversion or Exercise Price of Derivative Security   5.   Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		   6.   Nature of Indirect Beneficial Ownership
(Instr. 5)
                                 
       
                       
            Date
Exercisable		   Expiration
Date		       Title   Amount or Number of Shares                        
                                                     
                                                     

Explanation of Responses:

(1)
The shares reported in this response are directly beneficially owned by BVF Partners L.P., a Delaware limited partnership ("Partners"), the designated filer of this joint filing on Form 3, and its general partner, BVF Inc., a Delaware Corporation ("BVF, Inc."), which is also an investment advisor to Partners. Partners is the general partner of Biotechnology Value Fund, L.P., a Delaware limited partnership ("BVF, L.P."), an investment limited partnership that directly beneficially owns 951,685 of the shares of Common Stock reported in Table I. Partners is also the general partner of Biotechnology Value Fund II, L.P., a Delaware limited partnership ("BVF2"), an investment limited partnership which directly beneficially owns 537,450 of the shares of Common Stock reported in Table I. Partners is the manager of BVF Investments, L.L.C., a Delaware limited liability company ("Investments"), which beneficially owns 1,450,600 of the shares of Common Stock reported in Table I. Pursuant to the operating agreement of Investments, Partners is authorized, among other things, to invest the funds of Ziff Asset Management, L.P., the majority member of Investments, in the shares of Common Stock reported in Table I as being beneficially owned by Investments. Mark N. Lampert is, for the purpose of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the beneficial owner of any equity securities covered by this joint filing.


 
 
 
 
 
 
 
    BVF Partners L.P.    

 
 
By:
 
BVF Inc., its general partner

 
 
By:
 
/s/  MARK N. LAMPERT      
** Signature of Reporting Person
 
April 16, 2003
Date

**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Page 2 of 3

FORM 3 (Continued)   List of the names and addresses of other reporting persons:    
1.   Biotechnology Value Fund, L.P.   BIOTECHNOLOGY VALUE FUND, L.P.    
    227 West Monroe Street, Suite 4800              
    Chicago, Illinois 60606   By: BVF Partners L.P., its general partner
                   
          By: BVF Inc., its general partner
                   
            By: /s/  MARK N. LAMPERT      
**Signature of Reporting Person
    Authorized Signatory		   April 16, 2003
Date
                   
2.   Biotechnology Value Fund II, L.P.   BIOTECHNOLOGY VALUE FUND II, L.P.
    227 West Monroe Street, Suite 4800              
    Chicago, Illinois 60606   By: BVF Partners L.P., its general partner
                   
          By: BVF Inc., its general partner
                   
            By: /s/  MARK N. LAMPERT      
**Signature of Reporting Person
    Authorized Signatory		   April 16, 2003
Date
                   
3.   BVF Investments, L.L.C.   BVF INVESTMENTS, L.L.C.
    227 West Monroe Street, Suite 4800              
    Chicago, Illinois 60606   By: BVF Partners L.P., its manager    
                   
          By: BVF Inc., its general partner
                   
            By: /s/  MARK N. LAMPERT      
**Signature of Reporting Person
    Authorized Signatory		   April 16, 2003
Date
                   
4.   BVF Inc.   BVF INC.
    One Sansome Street, 31st Floor              
    San Francisco, California 94104   By: /s/  MARK N. LAMPERT      
**Signature of Reporting Person
    Authorized Signatory		   April 16, 2003
Date
                   
5.   Mark N. Lampert
One Sansome Street, 31st Floor
San Francisco, California 94104		   By: /s/  MARK N. LAMPERT      
**Signature of Reporting Person
    Authorized Signatory		   April 16, 2003
Date

**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Page 3 of 3